Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use.

During the past decade, a large number of cell-based medicinal products have been tested in clinical trials for the treatment of various diseases and tissue defects. However, licensed products and those approaching marketing authorization are still few. One major area of challenge is the manufacturing and quality development of these complex products, for which significant manipulation of cells might be required. While the paradigms of quality, safety and efficacy must apply also to these innovative products, their demonstration may be demanding. Demonstration of comparability between production processes and batches may be difficult for cell-based medicinal products. Thus, the development should be built around a well-controlled manufacturing process and a qualified product to guarantee reproducible data from nonclinical and clinical studies.

[1]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[2]  M. Suematsu,et al.  Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. , 2013, Cell stem cell.

[3]  P. Layrolle,et al.  Pericyte-Like Progenitors Show High Immaturity and Engraftment Potential as Compared with Mesenchymal Stem Cells , 2012, PloS one.

[4]  G. Pellegrini,et al.  Location and Clonal Analysis of Stem Cells and Their Differentiated Progeny in the Human Ocular Surface , 1999, The Journal of cell biology.

[5]  L Partington,et al.  Biochemical changes caused by decellularization may compromise mechanical integrity of tracheal scaffolds. , 2013, Acta biomaterialia.

[6]  Sadik H. Kassim,et al.  From lipoproteins to chondrocytes: a brief summary of the European Medicines Agency's regulatory guidelines for advanced therapy medicinal products. , 2013, Human gene therapy.

[7]  T. Graf,et al.  Historical origins of transdifferentiation and reprogramming. , 2011, Cell stem cell.

[8]  Wendell A. Lim,et al.  Cell-Based Therapeutics: The Next Pillar of Medicine , 2013, Science Translational Medicine.

[9]  D. Kirouac,et al.  The systematic production of cells for cell therapies. , 2008, Cell stem cell.

[10]  Krishanu Saha,et al.  Technical challenges in using human induced pluripotent stem cells to model disease. , 2009, Cell stem cell.

[11]  Elias A. Rivera,et al.  Potency evaluation of tissue engineered and regenerative medicine products. , 2013, Trends in biotechnology.

[12]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[13]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[14]  Christopher A Bravery,et al.  Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. , 2013, Cytotherapy.

[15]  K. Tarte,et al.  Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints. , 2013, Cytotherapy.

[16]  M. Serrano,et al.  Reprogramming in vivo produces teratomas and iPS cells with totipotency features , 2013, Nature.

[17]  Ji-yeon Lee,et al.  In vitro and in vivo analyses of human embryonic stem cell‐derived dopamine neurons , 2005, Journal of neurochemistry.

[18]  C. Mason,et al.  Bioprocess Forces and Their Impact on Cell Behavior: Implications for Bone Regeneration Therapy , 2011, Journal of tissue engineering.

[19]  G. Korbutt,et al.  Insulin expressing cells from differentiated embryonic stem cells are not beta cells , 2004, Diabetologia.

[20]  Hemanthram Varadaraju,et al.  Downstream Technology Landscape for Large-Scale Therapeutic Cell Processing , 2013 .

[21]  Andrew Buchanan,et al.  Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  M. Betjes,et al.  Mesenchymal stromal cells for organ transplantation: different sources and unique characteristics? , 2014, Current opinion in organ transplantation.

[23]  N. Benvenisty,et al.  The tumorigenicity of human embryonic stem cells. , 2008, Advances in cancer research.

[24]  David J Williams,et al.  Concise Review: Mind the Gap: Challenges in Characterizing and Quantifying Cell- and Tissue-Based Therapies for Clinical Translation , 2010, Stem cells.

[25]  D. Cyranoski iPS cells in humans , 2013, Nature Biotechnology.

[26]  M. Baker Court lifts cloud over embryonic stem cells , 2013, Nature.

[27]  J. Marchal,et al.  Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction. , 2014, Cytotherapy.

[28]  E. Jones,et al.  Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies , 2008, Mechanisms of Ageing and Development.

[29]  A. Caplan,et al.  Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine , 2013, Experimental & Molecular Medicine.

[30]  Canary Wharf,et al.  Reflection paper on classification of advanced therapy medicinal products , 2012 .

[31]  M. Neubauer,et al.  Mesenchymal stromal cell characteristics vary depending on their origin. , 2013, Stem cells and development.

[32]  L. Looijenga,et al.  Lessons from human teratomas to guide development of safe stem cell therapies , 2012, Nature Biotechnology.